Eli Lilly (LLY) Return on Sales (2009 - 2026)

Eli Lilly (LLY) has 17 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q1 2026 and bottomed at 0.0% in Q3 2023.
• The 5-year median for Return on Sales is 0.0% (2022), against an average of 0.0%.
• Peak annual rise in Return on Sales reached 0 bps in 2022, while the deepest fall reached 0 bps in 2022.
• A 5-year view of Return on Sales shows it stood at 0.0% in 2022, then declined by 12 bps to 0.0% in 2023, then soared by 39 bps to 0.0% in 2024, then climbed by 6 bps to 0.0% in 2025, then grew by 9 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.

Peer Comparison